In response: We believe Dr. Kiyosawa and colleagues are correct that the main difference is the prevalence of HBeAg. This may account for the high morbidity and mortality rates found in Japanese HBsAg carriers who have initially normal liver function tests when evaluated, regardless of the HBe status (1). In fact, it has been suggested that HBeAg-positive carriers with normal liver function tests cannot be considered "healthy'' carriers because chronic hepatitis may return in these patients when an impaired immune function is restored (2) . On the other hand, the outcome of anti-HBe-positive carriers, as reported by Dr. Kiyosawa and colleagues, seems similar to the outcome we reported (3).
As far as the risk for hepatocellular carcinoma is concerned, in a recent follow-up study (>16 years) carried out in Canada, no cases of hepatocellular carcinoma were recognized in more than 400 HBsAg carriers who had initially normal liver function tests (4). This corroborates our findings that the risk for hepatocellular carcinoma is low among Caucasian asymptomatic HBsAg carriers. On the other hand, a slightly increased risk has been found in Japan compared with the general population, both in HBsAg carriers with normal liver function tests (1), regardless of the HBe status, and in anti-HBe-positive carriers, regardless of liver function test results (5). However, such risk has never been evaluated in truly healthy Japanese HBsAg carriers (that is, patients with normal liver function tests, and normal or nearly normal liver histologic findings). 
Roberto de Franchis, MD

Rochalimaea Infections
To the Editors: We read with interest the concise editorial by Drs. Tompkins and Steigbigel (1) accompanying our article (2) describing the only immunocompetent patients reported in the literature with angiomatosis in the absence of human immunodeficiency virus infection or drug-induced immune suppression. Stating that bacillary angiomatosis in immunocompetent adults had been previously reported, the authors incorrectly cited three articles describing patients who had fever and bacteremia caused by Rochalimaea species but did not have the vascular lesions of either bacillary angiomatosis or parenchymal bacillary pellosis (3) (4) (5) . The error is frequently made and could lead to further confusion. The distinction is important to clinicians because it assists in defining the spectrum of disease for Rochalimaea infections, which includes fever and bacteremia, endocarditis, and cat scratch disease as well as bacillary angiomatosis. In addition, it is important to epidemiologists and molecular biologists attempting to determine why only a subset of Rochalimaea infections is associated with vascular proliferative lesions.
In response:
We agree that the papers we cited in our editorial (1) reported the isolation of Rochalimaea species from apparently immunocompetent patients who had fever and bacteremia but not the cutaneous lesions described as bacillary angiomatosis. Drs. Tappero and Koehler and their coworkers have made the important observation that these vascular lesions can also occur in immunocompetent patients (2) . Future study is needed to describe more fully the spectrum of diseases caused by these organisms and the reasons for the varying manifestations in different persons. 
Roy T. Steigbigel, MD
Aminophylline and Cardiac Arrest
To the Editors: We agree with Viskin and coworkers (1) that aminophylline may have a role in the management of bradyasystolic cardiac arrest (2-4). However, optimism should be tempered by our lack of experience and the uncontrolled nature of Viskin and colleagues' experiment. It is surprising that the authors observed a response to aminophylline therapy within 30 seconds of administration, given the relatively prolonged circulation time previously documented for patients in cardiac arrest (5) . Was a central venous catheter used for administration? The absence of a control group makes it impossible to conclude with certainty that the return of spontaneous circulation resulted from aminophylline therapy. Finally, even though 11 of 15 patients with cardiac arrest refractory to epinephrine and atropine developed stable heart rhythms after therapy, 10 patients died within 4 to 15 days after resuscitation. Whether aminophylline therapy actually affects ultimate outcome remains uncertain.
In response: The poor ultimate outcome of our patients is best explained by study criteria requiring at least four injections before concluding that they failed "to respond to epinephrine and atropine"; thus, only patients with prolonged asystole were included in our study (1) . The ability of epinephrine plus aminophylline (as first-line treatment for asystole) to improve long-term outcome through faster re-establishment of spontaneous cardiac rhythm must, as Drs. Varon and Fromm point out, be proven by controlled studies. Currently, aminophylline can only be recommended for patients with bradyasystolic arrest in whom standard treatment (2) has failed.
In accordance with present recommendations (2), some of our patients received all drugs (including aminophylline) through antecubital veins. This was always followed by saline flushing. Circulation time during closed-chest cardiac massage (defined as the time needed for an injected marker to reach a peripheral artery) may be more than 60 seconds if the marker is injected through an antecubital vein and the time to peak levels at the artery site is measured (3). However, if the time to first appearance of the same marker is measured, values as low as 25 to 39 seconds may be obtained (3) . In view of the aminophylline dosage used in our study (250 mg in a 10-mL rapid bolus), the last value could better represent the time needed to achieve a cardiac effect. We recognize, however, that the time to response reported by the investigators involved in resuscitation could have been underestimated. 
Cost and Effectiveness of Hepatitis B Immunization
To the Editors: Bloom and colleagues (1) present a careful analysis of the cost-effectiveness of alternative hepatitis B virus immunization strategies. However, the conclusion that various hepatitis B virus screening and vaccination strategies are an inexpensive way to improve the health of the public may be stronger than they imply, at least in the intermediate years of the program.
Widespread vaccination reduces not only the chance of vaccinees becoming infected but also the risk for spreading the virus to others. By decreasing the population prevalence of transient or long-term viral carriers, health benefits accrue to those who are not immunized. Contagion models developed to predict the effect of this "herd immunity" on specific population-based programs are complex and require data not generally available (2, 3) . Generally, though, as vaccination programs proceed, the risk faced by unvaccinated persons decreases, because as more become immune, there are fewer people from whom one might catch the virus.
With a very successful program, the chance of infection might in time become so low that vaccination no longer confers many benefits at all. In this circumstance, persons might reasonably forego vaccination, because to them the costs simply are not worth the benefits. In effect, these persons take a "free ride" on the herd immunity provided by the past vaccination decisions of others (4) . Experimental evidence suggests that, indeed, some persons use this strategy when deciding whether to be immunized (5) .
Whether one views herd immunity as further reducing the incidence of disease or as reducing the need for a vaccine, the general point is that herd immunity can be an important consideration in models of contagious disease. The risk for hepatitis B virus infection ought to change through each 10-year cycle of the model, not only because newborns, adolescents, and adults have different risks for infection but also because of the overall decrease in the prevalence of carriers we would expect from the vaccination efforts of earlier cycles. In short, immunizing our children will protect our grandchildren.
David A. Asch, MD, MBA University of Pennsylvania School of Medicine Philadelphia, PA 19104
In response: We agree with Dr. Asch that we probably underestimated the cost-effectiveness of hepatitis B virus vaccination by not incorporating the effects of herd immunity in our analysis (1) . We also agree that quantifying the effects of herd immunity is extremely difficult when examining any vaccination strategy. Our study evaluated three strategies (universal vaccination, screening and vaccination of those with negative test results, no vaccination) in four populations (newborns, adolescents, general adults, high-risk adults).
We took conservative positions wherever possible; that is, we purposely underestimated benefits and increased costs, thereby reducing cost-effectiveness ratios of all vaccination strategies examined. We chose to determine clinical and economic outcomes of hepatitis B virus vaccination under "worst case" assumptions (2). The results indicating cost-effectiveness of selected vaccination strategies are thus robust. Omitting the effects of herd immunity is consistent with this position.
Three effects of such a conservative position should be noted. First, including effects of herd immunity would not have changed the study conclusion that universal hepatitis B virus vaccination is highly cost-effective. Second, our study results should be viewed as incremental, defining cost-effectiveness of the various vaccination strategies we studied before herd immunity is established. Third, the more optimistic assumptions suggested by Dr. Asch would improve the cost-effectiveness of the recommended strategies.
The burden of proof is always on the proponent of an intervention. When conservative assumptions produce highly costeffective results, the decision maker can be confident that the estimate will be the lowest that can be expected. Greater population benefits at no increased cost accruing in the real world of medical practice are a bonus. Our conservative conclusions indicate that there is no clinical or economic reason to delay or deny investing in protecting children and adolescents from hepatitis B virus. 
The Benefit of Increasing Sulfonylurea Dose
To the Editors: Caution should be exercised in interpreting the conclusions regarding the maximally effective dose of glipizide in the recent important paper by Stenman and colleagues (1) . First, the group of patients studied was markedly hyperglycemic. Furthermore, although they were somewhat improved, at the conclusion of the study they remained hyperglycemic. Can one make judgments regarding the efficacy of this drug in patients who have responded so poorly?
In addition, these patients represent a homogeneous population, whereas patients with type 2 diabetes are heterogeneous. Several studies indicate the possible utility of higher doses of glipizide in selected patients (2, 3) . Anecdotally, members of our ethnically mixed population show different sensitivities to glipizide. Several of our patients who are most sensitive to the effects of glipizide are of Scandinavian descent. Although hardly definitive, this suggests the possibility that other populations might show different dose-response curves to glipizide. At the least, studies such as Stenman and colleagues' should be done in other populations before treatments that may be generalized to all patients with type 2 diabetes are recommended. On the basis of this study, it is premature for physicians to decrease the dose of glipizide to 10 mg in patients receiving larger doses. We agree, however, that insulin therapy should be initiated in patients who remain hyperglycemic on maximally effective doses of sulfonylurea. 
The authors do not specify on which days the twice-weekly home glucose measurements were obtained. If the measurements were discretionary, this may be a confounding factor in that patients may have recorded their sugars when most compliant. Moreover, because blood sugars were self-monitored, patients were aware of any difference in their glycemic control and may have altered their diet accordingly. Interestingly, some patients had normal baseline HbA lc values yet experienced no hypoglycemia while receiving maximal doses of glipizide for 3 months.
The authors conclude that beta-cell function decreases in patients receiving higher doses of glipizide by measuring serum insulin levels after a test meal. However, enhancement of insulin secretion by sulfonylureas varies inversely with the underlying glucose concentration. Thus, if the baseline glucose level is lower, less insulin secretion by the beta-cells would be expected for a given glucose challenge.
Finally, the study group was small and heterogeneous and, according to the authors, individual responses to glipizide differed markedly. Given these issues, it might have been more useful to present the outcomes for all patients individually. Because results were presented as a group average, significant responses in some patients may have been diminished when combined with those patients who did not benefit from an increased glipizide dose. In response: Although Drs. Feinglos and Hollis and Dr. Epstein list several reservations about our data, they do not provide any firm evidence for the conclusion that increasing the sulfonylurea dose above 10 mg is associated with improved glycemic control. Such studies are lacking. The studies cited by Drs. Feinglos and Hollis highlight the problem. One study (1) represented an uncontrolled multicenter study that compared glipizide with several other agents, including phenformin, and the other study (2) compared two sulfonylureas that were started at different doses. No study tried to reduce the dose to test whether the dose increase was necessary. For example, in the second study (2), the glipizide dose was increased from a mean dose of 10.9 mg to 29.7 mg without any significant improvement in glucose control. The inverse correlation between glipizide dose and mean blood glucose level also suggests that the cost of a mean reduction in blood glucose level of 10 mg/dL is 30 mg of drug.
Matthew D. Epstein, MD
The weekdays on which blood glucose was measured at home were fixed for individual patients but could vary among patients. We have successfully used this approach in many studies over the years (3, 4) . Some patients with low baseline HbA lc concentrations did experience mild hypoglycemia while receiving maximal doses but also when receiving lower doses.
The above findings are not unique to glipizide. Glyburide also shows lack of an increased effect at concentrations over 200 nmol/L, equivalent to doses of less than 10 mg (5). We agree that the patient group was heterogeneous and that some were more hyperglycemic than others, although they had normal or high C-peptide concentrations. This, however, represents the target group of patients in whom an increase in the sulfonylurea dose is considered. Some persons (especially obese persons) may still benefit from higher doses of sulfonylureas, although the response to treatment could not be predicted. Given the lack of scientific evidence for an improved effect of glipizide or glyburide doses above 10 mg, it may be justified to reconsider 15 mg as a maximum dose, which should be exceeded in only rare cases.
We think that sulfonylurea treatment should be started earlier, when the drugs are still effective, but it should also be stopped earlier, when the drugs can no longer achieve the treatment goals. Postponing the decision to start insulin treatment by further increasing the sulfonylurea dose does not benefit the patient.
Leif Groop, MD Svante Stenman, MD Per-Henrik Groop, MD Helsinki University Central Hospital 00170 Helsinki, Finland
Vital Capacity as a Predictor of Premature Death
To the Editors: Pryor and colleagues' article (1) should interest all primary care physicians who want to pursue a costeffective approach to the diagnosis and treatment of coronary artery disease. Their study, however, ignores one of the best indicators of premature morbidity and mortality from heart disease, namely, vital capacity obtained from simple spirometry (2) . Indeed, all excess mortality can be predicted by spirometric measurements (3) . First introduced to medicine in 1846 by the surgeon John Hutchinson (4), the spirometer may be as useful in the office of all primary care physicians as electrocardiographic machines in identifying patients at risk for premature coronary artery disease. It is also useful for predicting premature morbidity and mortality from lung disease (5).
In response: We appreciate Dr. Petty's interest in and support of our article (1) . Before rushing out to equip every primary care physician's office with a spirometer, however, we would point out the differences between our study and those cited by Dr. Petty.
All our patients reported chest pain thought to require subsequent diagnostic testing. Studies cited by Dr. Petty (2, 3) focused on a healthy, asymptomatic population. The distinction is important for two reasons. First, the independent prognostic value of characteristics in healthy asymptomatic patients may be substantially lower in symptomatic patients after adjusting for known prognostic characteristics. For example, the added prognostic importance of traditional risk factors in coronary disease is small when the patient's symptoms (of angina and congestive heart failure), degree of myocardial damage, anatomy, and ventricular function are considered. Second, as William Stead has said, "It's hard to make an asymptomatic patient feel better." The use of a test should be considered in the context of how it can improve outcome by changing patient management. 
David B. Pryor, MD
The Familial Muir-Torre Syndrome
To the Editors: Colorectal cancer tends to aggregate in families. A small fraction of these families have adenomatous polyposis coli caused by inherited mutations in the APC gene on chromosome 5q (1) . Hereditary nonpolyposis colon cancer is more common although heterogeneous and difficult to define (2) . We recently identified a family with exceptionally prominent features of the Muir-Torre syndrome, a clinically distinct form of hereditary nonpolyposis colon cancer characterized by sebaceous neoplasms of the skin and associated with cancers of the colon, rectum, and genitourinary tract (3).
The proband (patient III-2) developed carcinomas of the kidney and colon at 48 and 49 years of age, respectively (Figure 1 stomach, duodenum, jejunum, colon, and rectum during a 29-year period. In addition, several villous adenomas of the colon and two cutaneous sebaceous adenomas were excised. Cancers in patients with the Muir-Torre syndrome are reported to have an indolent course, even after metastases have developed (3). The syndrome occurs in an autosomal dominant pattern in some families, but clustering of multiple primary cancers among several relatives is rare. To confirm the diagnosis of the Muir-Torre syndrome, dermatologic consultation was requested for our proband and his cousin (patient 111-15). Skin biopsy specimens showed previously unsuspected sebaceous adenomas in both patients. Sebaceous adenoma identifies the subset of families with hereditary nonpolyposis colon cancer who have the Muir-Torre syndrome and those at increased cancer risk. These family members should be monitored to detect early cancers and perhaps should be enrolled in chemoprevention trials. Genetic studies can help identify the inherited molecular defect that causes the Muir-Torre syndrome. 
Pancreatitis Possibly Related to 2'-3'-Dideoxycytidine
To the Editors: To improve the treatment of the acquired immunodeficiency syndrome, clinical trials are under way in which the nucleoside analogs 2',3'-dideoxycytidine (ddC) and 3'-azido-2'3'-dideoxythymidine (zidovudine, AZT) are being tested simultaneously, intermittently, or in an alternating regimen (1, 2). Combination of these two antiretroviral agents might allow the use of lower or less frequent doses, thus minimizing the individual or selective drug toxicities or both (1) . None of the preliminary reports published have identified acute pancreatitis as a toxic effect of ddC (3). Preliminary reports of clinical trials using another nucleoside analog, 2',3'-dideoxyinosine (ddl), mention sporadic cases of acute pancreatitis as a side effect (3).
In August 1991, a 45-year-old woman was admitted to our emergency room for evaluation of nausea, vomiting, and severe abdominal pain lasting less than 72 hours. The clinical impression was acute pancreatitis, possibly drug-induced. The patient denied drug or alcohol abuse. Past medical history was remarkable for a positive human immunodeficiency virus test and Pneumocystis carinii pneumonia. She began taking zidovudine on 22 September 1990 and one tablet of trimethoprimsulfamethoxazole daily (800 mg and 160 mg per tablet, respectively) for P. carinii pneumonia prophylaxis in November 1990. She tolerated both drugs well for 1 year. Approximately 6 weeks before admission, the patient was enrolled in a triplearm, double-blind, national clinical trial study (started on 7 July 1991) to evaluate the use of ddC and zidovudine. When the patient's protocol code was broken shortly before she died, she was found to be receiving both drugs.
Autopsy findings showed extensive fat and parenchymal hemorrhagic necrosis of the pancreas. Light microscopy showed coagulation necrosis, hemorrhage, and accumulation of neutrophils. These changes are characteristic of acute pancreatitis.
We could not confirm a direct causal relation between ddC and acute pancreatitis in this case; however, after microbio-logic studies and the use of light and electron microscopy, we ruled out other possible causes of pancreatitis (4). A good temporal relation exists between the administration of ddC and the appearance of symptoms; therefore, we accepted the association. We speculate that ddC or its metabolites, or both, interfere with the pancreatic process of the exocytosis of zymogen granules, resulting in granular accumulation and subsequent intracellular lysosomal fusion (5). Future studies will better define the use of the nucleoside analogs; in the meantime, physicians need to be aware of the possible association between ddC and pancreatitis. The assessment of the pulse character is an important part of clinical examination. Textbooks generally recommend using either the brachial or the carotid pulse to assess the arterial waveform and make no reference to the character of lowerlimb pulses. This recommendation is entirely appropriate when dealing with acquired heart disease, but in congenital heart disease, the presence of interruption of the aortic arch with arterial duct supply to the descending aorta creates the potential for differing upper-and lower-limb pulses. When both great vessels originate from the same ventricle and the arterial duct is not restrictive, no clinical difference is found between upperand lower-limb pulses. The development of a collapsing upperlimb pulse in a patient with normal cardiac connections often suggests aortic regurgitation. In the patient described, however, with interruption of the aortic arch and pulmonary artery supply to the lower limbs, the development of collapsing lower-limb pulses with "normal" upper-limb pulses is virtually diagnostic of pulmonary valve regurgitation. Given the clinical setting, this finding strongly pointed to a diagnosis of pulmonary valve endocarditis. This problem can be divided into three major categories. First, some reports do not include enough information to allow the reader to fully assess the logistic model applied. This category encompasses all reports that include odds ratios and confidence intervals but lack information about the sample size or the statistical power of the model, making it unclear whether there is a true absence of an association or insufficient power to detect one. The second category comprises those reports in which the goodness of fit of the model is not assessed and one is unable to determine how well the model describes the data. The third category consists of those reports that give ample statistical nuances about the model but lack a clear research hypothesis. The authors focus on including a number of variables in the model and not on whether including them as covariates makes reasonable biologic sense. The inclusion of a covariate unrelated to the outcome variable or the omission of an important covariate modifies the regression coefficients, thus biasing the odds ratio estimates. Regression procedures are simply the means for analysis, not the end of an investigation.
Sandra
Given the large number of papers submitted for publication and the limited journal space, editors must make difficult decisions concerning what kind of information about the regression models should be included and what should be excluded and made available on request. It would be useful if clear-cut publication criteria for generalized linear models were included in forthcoming statistical guidelines for contributors to medical journals.
Carlos CampillOy MD Pan American Health Organization Washington, DC 20037
To the Editors: I immensely enjoyed the article by Dr. LaCombe (1) . It embodied those ideals and goals that I believe are of central importance in the practice of medicine.
The statement, "our profession is a way of life itself, nothing else comes close," has already made it easier for me to handle some of the mundane choices of everyday "red tape." Like Dr. LaCombe, I am an internist, but I am a subspecialist (pulmonologist); still, 50% of my practice is general internal medicine because I love it, especially when I see a patient in our emergency room whose being there seems to cry out, "What this patient (and his family) needs is a doctorV I, too, practice in a small town, make house calls, barter with some patients (many of whom are Amish), and try to make each patient "encounter a positive experience for both the patient and me."
I do not know all the answers, but one thought that is always with me when faced with a dilemma is this quotation from Brecht: "The aim of science is not to open the door to infinite wisdom, but to set a limit to infinite error."
William H. Fee, Jr., MD Chest Medicine Associates Franklin, PA 16323
